(Q35751844)

10 August 2017

1 reference

title

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough (English)

1 reference

10 August 2017

1 reference

1

Anthony E Lang

1 reference

10 August 2017

Jose A Obeso

2

1 reference

PubMed ID

15099546

10 August 2017

language of work or name

1 reference

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

3

1 reference

10 August 2017

309-316

1 reference

10 August 2017

5

1 reference

Neuroscience. Versatile cells against intractable diseases

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

From transplants to gene therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Prospects for gene therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Neurotrophic factors in Alzheimer's and Parkinson's disease brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Parkinson's disease. First of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Parkinson's disease. Second of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

The occurrence of depression in Parkinson's disease. A community-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Daytime sleepiness and other sleep disorders in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Risk of dementia in Parkinson's disease: a community-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Clinical and [18F] dopa PET findings in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Alpha-synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Hyperactivity of Remaining Dopaminergic Neurones after Partial Destruction of the Nigro-striatal Dopaminergic System in the Rat

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Compensations after lesions of central dopaminergic neurons: some clinical and basic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Plasticity of the nigropallidal pathway in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Dopaminergic innervation of human basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Glutamate and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Subthalamic GAD gene therapy in a Parkinson's disease rat model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Protection against dopaminergic nigrostriatal cell death by excitatory input ablation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Etiology and pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Where does parkinson disease pathology begin in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Is Parkinson's disease a primary olfactory disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Amygdala pathology in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

The anterior olfactory nucleus in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Neural transplantation for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Cell therapy in Parkinson's disease - stop or go?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Neural transplantation: a hope for patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Dyskinesias following neural transplantation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Stem cells in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900740-9

7 January 2021

10.1016/S1474-4422(04)00740-9

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15099546